Table 1.
Summary of patient and treatment characteristics, and treatment outcomes of the included randomized controlled trials. Outcome data are expressed at 5 years, unless indicated differently
| Author (year of publication) | Years of inclusion | No of patients | Mono/multi center | Treatment arms | Median FU (months) | Age (years) | FIGO stage (n (%)) | HT device | HT temp (median °C) | Outcome | |||||
| I | II | III | IV | LC/PC | DFS | OS | |||||||||
| Harima (2001)42 | 1994–1999 | 40 | Mono | RT vs RHT | 36 | 62 vs 65 | 0 (0) | 0 (0) | 40 (100) | 0 (0) | Capacitive | 40.6 | 10 vs 16* | 10 vs 16* | 48 vs 58* |
| Van der Zee (2002)35 | 1990–1996 | 114 | Multi | RT vs RHT | 43 | 56 vs 58 | 0 (0) | 22 (19) | 81 (71) | 11 (10) | Radiative | NA | 41 vs 61* | NA | 27 vs 51* |
| Vasanathan (2005) | 1998–2002 | 110 | Multi | RT vs RHT | 16 | 50 vs 45 | 0 (0) | 56 (51) | 51 (46) | 3 (3) | Capacitive | 41.6 | 69* | NA | 73* |
| Lutgens (2016)37 | 2003–2009 | 84 | Multi | CRT vs RHT | 85 | 53 | 18 (21) | 46 (55) | 18 (21) | 2 (3) | Radiative | NA | NA | 1.15† | 1.04† |
| Harima (2016)38 | 2001–2015 | 101 | Multi | CRT vs RCHT | 55 | 62 vs 60 | 1 (1) | 26 (26) | 66 (65) | 8 (8) | Capacitive | 41.1 | 71 vs 80 | 61 vs 71 | 65 vs 78 |
| Minnaar (2019)34 | 2014–2017 | 202 | Mono | CRT vs RCHT | 6 | 49 vs 48 | 0 (0) | 75 (36) | 2 (1) | 129 (63) | Capacitive | NA | 20 vs 39‡ | 20 vs 39‡ | 82 vs 87‡ |
| Wang (2020)39 | 2009–2013 | 373 | Mono | CRT vs RCHT | 60 | 50 vs 51 | 7 (2) | 230 (62) | 127 (34) | 9 (2) | Capacitive | 40.5 | NA | 83 vs 87 | 72 vs 82 |
Bold type indicates significant difference.
*Based on 3 years of follow-up.
†Based on 7 years of follow-up.
‡Based on 6 months of follow-up.
CRT, chemoradiation; DFS, disease free survival; FIGO, International Federation of Gynecology and Obsetrics 2008; FU, follow-up; HT, hyperthermia; LC, local control; NA, not available; OS, overall survival; PC, pelvic control; RCHT, chemoradiation with hyperthermia; RHT, radiotherapy and hyperthermia; RT, radiotherapy.